Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Jablons

Showing results (61-70 of 197) with videos related to

Pageof 20
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 4, 2011
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancerChien P Chen, Vivian K Weinberg, Thierry M Jahan, et al.
BMC Pharmacology & Toxicology|July 13, 2013
Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2Shu Liu, David Hsieh, Yi-Lin Yang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 16, 2003
c-Kit is not expressed in malignant mesotheliomaAndrew E Horvai, Li Li, Zhidong Xu, et al.
JAMA|October 25, 2012
A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumorsJohannes R Kratz, Stephen K Van den Eeden, Jianxing He, et al.
Anticancer Research|April 12, 2003
A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cellsCheng-Ta Yang, Liang You, Yu-Chin Lin, et al.
Clinical Lung Cancer|May 8, 2009
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directionsOliver Gautschi, Philip C Mack, Angela M Davies, et al.
Archives of Pathology & Laboratory Medicine|April 10, 2003
Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2Andrew E Horvai, Li Li, Zhidong Xu, et al.
American Journal of Clinical Oncology|January 30, 2013
Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavityChristian C Okoye, David M Jablons, Thierry M Jahan, et al.
Experimental Lung Research|October 27, 2020
Ponatinib is a potential therapeutic approach for malignant pleural mesotheliomaYi-Wei Yang, Angelica Marrufo, Jillian Chase, et al.
Head & Neck|May 1, 2008
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesisJosephine Chou, Yu-Ching Lin, Jae Kim, et al.
Pageof 20

Showing results (61-70 of 197) with videos related to

Sort By:
Pageof 20
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 4, 2011
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancerChien P Chen, Vivian K Weinberg, Thierry M Jahan, et al.
BMC Pharmacology & Toxicology|July 13, 2013
Coumestrol from the national cancer Institute's natural product library is a novel inhibitor of protein kinase CK2Shu Liu, David Hsieh, Yi-Lin Yang, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|August 16, 2003
c-Kit is not expressed in malignant mesotheliomaAndrew E Horvai, Li Li, Zhidong Xu, et al.
JAMA|October 25, 2012
A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumorsJohannes R Kratz, Stephen K Van den Eeden, Jianxing He, et al.
Anticancer Research|April 12, 2003
A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cellsCheng-Ta Yang, Liang You, Yu-Chin Lin, et al.
Clinical Lung Cancer|May 8, 2009
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directionsOliver Gautschi, Philip C Mack, Angela M Davies, et al.
Archives of Pathology & Laboratory Medicine|April 10, 2003
Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2Andrew E Horvai, Li Li, Zhidong Xu, et al.
American Journal of Clinical Oncology|January 30, 2013
Divergent management strategies for typical versus atypical carcinoid tumors of the thoracic cavityChristian C Okoye, David M Jablons, Thierry M Jahan, et al.
Experimental Lung Research|October 27, 2020
Ponatinib is a potential therapeutic approach for malignant pleural mesotheliomaYi-Wei Yang, Angelica Marrufo, Jillian Chase, et al.
Head & Neck|May 1, 2008
Nasopharyngeal carcinoma--review of the molecular mechanisms of tumorigenesisJosephine Chou, Yu-Ching Lin, Jae Kim, et al.
Pageof 20